Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Randomized Double-Blind Study of Gantenerumab in Mild Alzheimer's Disease with Open-Label Extension
jRCT2080222585Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Aug 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing Gantenerumab with Placebo / Gantenerumab OLE (2 arms). Started Aug 2014; status: completed.
02
Drugs
gantenerumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCT2080222585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222585.